RxDoctor Payments Data

Alicia Carden, APRN

Psychiatric/Mental Health · Melbourne, FLNPI 1942688403

Payments from drug & device makers

$3,862in general payments, 2019–2025

Across 243 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$485
  • Teva Pharmaceuticals USA, Inc.$478
  • Axsome Therapeutics, Inc.$464
  • AbbVie$445
  • Neurocrine Biosciences, Inc.$327
  • E.r. Squibb & Sons, L.L.C.$300
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$3,79698%
  • Education$662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,862 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$8,510
Medicare patients
56
Services billed
152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate68$239,410
IngrezzaValbenazine Tosylate12$101,614
RexultiBrexpiprazole66$101,081
VraylarCariprazine Hcl50$73,500
FanaptIloperidone13$45,583
CaplytaLumateperone Tosylate25$42,154
AuvelityDextromethorphan Hbr/Bupropion39$34,937
TrintellixVortioxetine Hydrobromide59$33,654
Lurasidone Hcl107$16,329
Vilazodone Hcl135$13,108
Aripiprazole236$11,576
AdderallDextroamphetamine/Amphetamine11$7,118
Quetiapine Fumarate329$6,347
Trazodone Hcl520$5,841
Clozapine25$5,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$250$239,41068 claims
Neurocrine Biosciences, Inc.Ingrezza$327$101,61412 claims
Otsuka America Pharmaceutical, Inc.Rexulti$485$101,08166 claims
AbbVieVraylar$445$73,50050 claims
Vanda Pharmaceuticals Inc.Fanapt$215$45,58313 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$197$42,15425 claims
Axsome Therapeutics, Inc.Auvelity$464$34,93739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →